Your browser doesn't support javascript.
loading
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Blood ; 115(22): 4393-402, 2010 Jun 03.
Article in En | MEDLINE | ID: mdl-20194898

Full text: 1 Database: MEDLINE Main subject: B-Lymphocytes / Antigens, CD20 / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Blood Year: 2010 Type: Article Affiliation country: Switzerland

Full text: 1 Database: MEDLINE Main subject: B-Lymphocytes / Antigens, CD20 / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Blood Year: 2010 Type: Article Affiliation country: Switzerland